• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

    12/6/22 4:06:37 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DMAC alert in real time by email
    SC 13G/A 1 sc13ga-12062022.htm SCHEDULE 13G



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)*
    DiaMedica Therapeutics Inc.

    (Name of Issuer)


    Common Shares, no par value

    (Title of Class of Securities)


    25253X207

    (CUSIP Number)


    July 8, 2022

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      ☐  Rule 13d-1(b)

      ☒  Rule 13d-1(c)

      ☐   Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).








    CUSIP No.
    25253X207
    13G/A
    Page 2 of 8



    1
    NAMES OF REPORTING PERSONS

    TomEnterprise AB
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
    (a)         ☐
    (b)         ☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Sweden

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0

    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0%  (See Item 4)*
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS
     
    FI
     



    CUSIP No.
    25253X207
    13G/A
    Page 3 of 8


    1
    NAMES OF REPORTING PERSONS

    TomEqt Private AB
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
    (a)         ☐
    (b)         ☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Sweden

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,855,847 Common Shares
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,855,847 Common Shares

    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,855,847 Common Shares
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    10.8% (See Item 4)*
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS
     
    FI
     


    CUSIP No.
    25253X207
    13G/A
    Page 4 of 8


    1
    NAMES OF REPORTING PERSONS

    Thomas Von Koch
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
    (a)         ☐
    (b)         ☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Sweden

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,855,847 Common Shares
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,855,847 Common Shares

    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,855,847 Common Shares
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    10.8% (See Item 4)*
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS
     
    IN
     


    CUSIP No.
    25253X207
    13G/A
    Page 5 of 8

    Item 1(a).  Name of Issuer:
    DiaMedica Therapeutics Inc.
    Item 1(b).  Address of Issuer’s Principal Executive Offices:
    DiaMedica Therapeutics Inc.
    Two Carlson Parkway, Suite 260
    Minneapolis, Minnesota 55447
    Item 2(a).  Name of Person Filing:
    This statement is filed by the entities and persons listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the Common Shares (as defined in Item 2(d) below) of the Company:
    Record Holder
    TomEqt Private AB is the record holder of the Common Shares.
    Reporting Individual
    Mr. Thomas Von Koch is the Board Member and beneficial owner of TomEqt Private AB.
    Item 2(b).  Address of Principal Business Office or, if None, Residence:
    The address of the business office of each of the Reporting Persons is:

    c/o KinKon AB
    Biblioteksgatan 25
    11435
    Stockholm, Sweden
    Item 2(c).  Citizenship:
    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
    Item 2(d).  Title of Class of Securities:
    Common Shares, no par value (the “Common Shares”)
    Item 2(e).  CUSIP Number:
    25253X207
    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person  filing is a:
    (a)-(k):   Not applicable
    Item 4.  Ownership.


    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 26,443,067 shares of Common Stock issued and outstanding as of November 7, 2022.

    CUSIP No.
    25253X207
    13G/A
    Page 6 of 8


    TomEqt Private AB is the record holder of the Common Shares.  Mr. Thomas Von Koch, as the Board Member of TomEqt Private AB, has the sole power to vote and dispose of the Common Shares and is deemed to be the beneficial owner of all the Common Shares.

    Item 5.  Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable

    Item 8.  Identification and Classification of Member of the Group.

    Not applicable.

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10.  Certification.

    By signing below the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11 under the Securities Exchange Act of 1934, as amended.

    CUSIP No.
    25253X207
    13G/A
    Page 7 of 8

    SIGNATURE
     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    TOMENTERPRISE AB
         
    Dated: December 6, 2022
    By:
    /s/ Thomas Von Koch
       
    Board Member
     
     
     
     
     
    TOMEQT PRIVATE AB
     
         
    Dated: December 6, 2022
    By:
    /s/ Thomas Von Koch
       
    Board Member
         
         
    Dated: December 6, 2022
    /s/ Thomas Von Koch
     
    Board Member
         



    CUSIP No.
    25253X207
    13G/A
    Page 8 of 8



    EXHIBIT 1

    JOINT ACQUISITION STATEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.


     
    TOMENTERPRISE AB
         
    Dated: December 6, 2022
    By:
    /s/ Thomas Von Koch
       
    Board Member
     
     
     
     
     
    TOMEQT PRIVATE AB
     
         
    Dated: December 6, 2022
    By:
    /s/ Thomas Von Koch
       
    Board Member
         
         
    Dated: December 6, 2022
    /s/ Thomas Von Koch
     
    Board Member
         




    Get the next $DMAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DMAC

    DatePrice TargetRatingAnalyst
    10/7/2024$7.00Buy
    H.C. Wainwright
    4/24/2024$8.00Buy
    Craig Hallum
    6/22/2023$7.00Perform → Outperform
    Oppenheimer
    6/30/2021$38.00 → $32.00Buy
    Roth Capital
    More analyst ratings

    $DMAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by DiaMedica Therapeutics Inc.

      SC 13G - DiaMedica Therapeutics Inc. (0001401040) (Subject)

      7/8/24 5:23:49 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

      SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)

      6/27/23 4:12:06 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

      SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)

      6/27/23 4:11:32 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company will participate in upcoming investor conferences in May 2025. 2025 RBC Capital Markets Global Healthcare Conference Tuesday, May 20th – Wednesday, May 21st, 2025, in New York City, New York. Management will be available for one-on-one meetings throughout the conference. H.C. Wainwright 3rd Annual BioConnect Conference Tuesday, May 20th, 2025, in New York City, New York. Management will participate in a fireside chat at 3:30 PM ET, which will be available via webcast at https://journey.ct.events/view/cb8

      5/8/25 4:00:00 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13th. DiaMedica will host a live conference call on Wednesday, May 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, May 14, 2025 Time: 8:00 AM ET / 7:00 AM CT Web access: https://app.webinar.net/24NpV0mjklG Dial In: (800) 836-8184 Conference ID: 93262 Interested parties may access the

      5/7/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

      Conference Call and Webcast March 18 at 8:00 AM Eastern Time / 7:00 AM Central Time  Preeclampsia Phase 2 Trial Preliminary Topline Safety and Efficacy Data from Part 1A of the Study Expected in the Second Quarter of 2025 Acute Ischemic Stroke Phase 2/3 Program Enrollment Ongoing Appointed Experienced Biotech Executive Daniel J. O'Connor to the Board Cash Runway into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the year ended December 31, 2024. Management will host a conference call Tuesday, M

      3/17/25 4:30:00 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Von Koch Thomas bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      7/1/24 4:27:16 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Stahlberg Jan bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      7/1/24 4:24:38 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wambeke David J. bought $49,200 worth of Voting Common Shares (20,000 units at $2.46), increasing direct ownership by 4% to 527,114 units (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      11/16/23 4:37:28 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Financials

    Live finance-specific insights

    See more
    • DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13th. DiaMedica will host a live conference call on Wednesday, May 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, May 14, 2025 Time: 8:00 AM ET / 7:00 AM CT Web access: https://app.webinar.net/24NpV0mjklG Dial In: (800) 836-8184 Conference ID: 93262 Interested parties may access the

      5/7/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

      Conference Call and Webcast March 18 at 8:00 AM Eastern Time / 7:00 AM Central Time  Preeclampsia Phase 2 Trial Preliminary Topline Safety and Efficacy Data from Part 1A of the Study Expected in the Second Quarter of 2025 Acute Ischemic Stroke Phase 2/3 Program Enrollment Ongoing Appointed Experienced Biotech Executive Daniel J. O'Connor to the Board Cash Runway into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the year ended December 31, 2024. Management will host a conference call Tuesday, M

      3/17/25 4:30:00 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its full-year 2024 financial results will be released after the markets close on Monday, March 17th. DiaMedica will host a live conference call on Tuesday, March 18th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Tuesday, March 18, 2025 Time: 7:00 AM CDT / 8:00 AM EDT Web access: https://app.webinar.net/yzor97w9Nvj Dial In: (800) 836-8184 Conference ID: 50034 Interested parties may access the conference call

      3/11/25 8:23:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pilnik Richard D. exercised 24,000 units of Voting Common Shares at a strike of $2.11, increasing direct ownership by 8% to 312,995 units (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      4/8/25 4:41:36 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director O'Connor Daniel J.

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      2/24/25 5:06:33 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider O'Connor Daniel J.

      3 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      2/24/25 4:54:22 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on DiaMedica Therapeutics with a new price target

      H.C. Wainwright initiated coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $7.00

      10/7/24 7:50:42 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum resumed coverage on DiaMedica Therapeutics with a new price target

      Craig Hallum resumed coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $8.00

      4/24/24 8:38:29 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded DiaMedica Therapeutics from Perform to Outperform and set a new price target of $7.00

      6/22/23 7:34:26 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Leadership Updates

    Live Leadership Updates

    See more
    • DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. Mr. O'Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive level leadership positions at Ambrx Biopharma, Inc. (Ambrx), ImClone Systems Incorporated, Bracco Diagnostics, and PharmaNet (today, Syneos Health). Mr. O'Connor has gained a reputation as a seasoned and successful biopharma CEO, most recently serving as President, Chief Executive Officer and Director of Ambrx, wher

      2/24/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

      Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

      1/22/24 8:23:00 AM ET
      $DMAC
      $MRNS
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

      Dr. Shah Has Spent Over Two Decades Leading Biological Development Teams at Biotechnology Companies and Has Deep Expertise in Protein Development and Manufacturing DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer. Dr. Shah will lead the development of DiaMedica's manufacturing operations for the late-stage drug candidate DM199. Since May 2023, Dr. Shah has been advising DiaMedica as it worked through the final resolution of the clinical hold on the investigational new drug applic

      9/12/23 8:13:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    SEC Filings

    See more
    • SEC Form DEFA14A filed by DiaMedica Therapeutics Inc.

      DEFA14A - DiaMedica Therapeutics Inc. (0001401040) (Filer)

      3/28/25 7:15:59 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by DiaMedica Therapeutics Inc.

      DEF 14A - DiaMedica Therapeutics Inc. (0001401040) (Filer)

      3/28/25 7:14:24 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by DiaMedica Therapeutics Inc.

      10-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)

      3/17/25 4:32:31 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care